PharmaShots | Incisive News in 3 Shots

Subscribe Now

NCT02792699

Amgen and Allergan Report Results of ABP 798 (rituximab- biosimilar) in P-I/III (NCT02792699) for Moderate-To-Severe Rheumatoid Arthritis (RA)

Amgen and Allergan Report Results of ABP 798 (rituximab- biosimilar) in P-I/III (NCT02792699) for Moderate-To-Severe Rheumatoid Ar...

January 24, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us